PLoS ONE (Jan 2024)

A novel assay to measure low-density lipoproteins binding to proteoglycans.

  • Esmond N Geh,
  • Debi K Swertfeger,
  • Hannah Sexmith,
  • Anna Heink,
  • Pheruza Tarapore,
  • John T Melchior,
  • W Sean Davidson,
  • Amy Sanghavi Shah

DOI
https://doi.org/10.1371/journal.pone.0291632
Journal volume & issue
Vol. 19, no. 1
p. e0291632

Abstract

Read online

BackgroundThe binding of low-density lipoprotein (LDL) to proteoglycans (PGs) in the extracellular matrix (ECM) of the arterial intima is a key initial step in the development of atherosclerosis. Although many techniques have been developed to assess this binding, most of the methods are labor-intensive and technically challenging to standardize across research laboratories. Thus, sensitive, and reproducible assay to detect LDL binding to PGs is needed to screen clinical populations for atherosclerosis risk.ObjectivesThe aim of this study was to develop a quantitative, and reproducible assay to evaluate the affinity of LDL towards PGs and to replicate previously published results on LDL-PG binding.MethodsImmunofluorescence microscopy was performed to visualize the binding of LDL to PGs using mouse vascular smooth muscle (MOVAS) cells. An in-cell ELISA (ICE) was also developed and optimized to quantitatively measure LDL-PG binding using fixed MOVAS cells cultured in a 96-well format.ResultsWe used the ICE assay to show that, despite equal APOB concentrations, LDL isolated from adults with cardiovascular disease bound to PG to a greater extent than LDL isolated from adults without cardiovascular disease (pConclusionWe have developed an LDL-PG binding assay that is capable of detecting differences in PG binding affinities despite equal APOB concentrations. Future work will focus on candidate apolipoproteins that enhance or diminish this interaction.